ALL THE NEWS
This Week in The Roadhouse Pharmacy
/in Uncategorized /by Wally GrahamTHE ROADHOUSE PHARMACY: There’s a great deal of interest in the Bio-tech sector at the moment, so we have opened our own Pharmacy to keep our readers up to speed. Patrys completes successful clinical trial Patrys Limited (ASX: PAB) has received final results from a Phase I/IIa, open-label study of PAT-SM6 in patients with refractory […]
Raising funds across the Boards
/in Uncategorized /by Wally GrahamTHE FUND RAISER: There’s been some happy explorers boosting their coffers this week. $2.1 million to accelerate El Roble Mining Group (ASX: MNE) has received commitments to raise up to approximately $2.1 million by way of a placement of up to 75 million fully paid ordinary shares at an issue price of 2.8 cents per […]
What the Brokers Say
/in Uncategorized /by Wally GrahamWHAT THE BROKERS SAY: Interesting news and views from across the Resource Analyst universe. www.breakawayresearch.com Auroch Minerals (ASX: AOU) Auroch Minerals’ (ASX: AOU) Manica gold project hosts a significant JORC Resource of 48.9 million tonnes at 1.79 grams per tonne gold for 2.82 million ounces. The company now has put in place a clear three […]
Mines and Money Hong Kong
/in Uncategorized /by Wally GrahamTHE CONFERENCE CALLER: Mining, so the experts say, is a cyclical industry with the current cycle not pedalling along at quite the same clip as when the boom was in full swing. Although it has, to my knowledge, never been proved scientifically, it seems that when you place a large number of people from the […]
Red tape ‘Repeal Day’
/in Uncategorized /by Wally GrahamIN THE LOBBY: On the eve of the APPEA conference in Perth next week The Minerals Council of Australia and The Australian Petroleum Production & Exploration Association released a joint statement on the Federal Government’s Red tape ‘Repeal Day’. The groups banded together as Australia’s resources sector to welcome the Federal Government’s efforts to curb […]
Navarre encounters more shallow copper-gold at Eclipse
/in The Drill Sergeant /by Wally GrahamTHE DRILL SERGEANT: Navarre Minerals (ASX: NML) has announced further gold and copper results from the final batch of samples it has received from a recent 11 hole Reverse Circulation (RC) drilling program carried out at the company’s 100 per cent‐owned Eclipse copper‐gold prospect, located northwest of Melbourne in the Miga Arc copper belt. Navarre […]
Paringa Scoping Study confirms Buck Creek fundamentals
/in The Drill Sergeant /by Wally GrahamTHE DRILL SERGEANT: Paringa Resources (ASX: PNL) has announced the results of a JORC Code 2012 and NI43-101 compliant Scoping Study conducted on the north eastern quadrant of the company’s Buck Creek thermal coal project in Kentucky, USA. The study used the projects current coal Resource Estimate of 154 million tons of coal, and determined […]
Bone Medical ties up BN006 research collaboration
/in Uncategorized /by Wally GrahamTHE ROADHOUSE PHARMACY: Bone Medical Ltd (ASX: BNE) has entered into a research agreement with William Harvey Research Limited (WHRL), to further study the company’s anti-inflammatory molecule for rheumatoid arthritis (RA), BN006, and support its progress towards clinical studies in man. WHRL is part of the William Harvey Research Institute in London and a world […]
Imugene allowed Israel patent for cancer vaccine
/in Uncategorized /by Wally GrahamTHE PHARMACY: Australian biopharmaceutical company Imugene Limited (ASX: IMU) has been issued an Intention to Grant notice from the Israeli Patent Office for the company’s proprietary cancer vaccine HER-Vaxx (Patent no. IL 194162, 2027expiry). In its announcement to the ASX Imugene explained HER-Vaxx to be a proprietary therapeutic cancer vaccine that stimulates a polyclonal antibody […]
Patrys advances PAT-LM1 to clinical development
/in Uncategorized /by Wally GrahamTHE PHARMACY: Clinical stage biotechnology company Patrys Limited (ASX: PAB) has released an update on the development program for the company’s anti-cancer product, PAT-LM1. Patrys said PAT-LM1 is the second IgM antibody in the company’s pipeline to enter clinical development. The company explained PAT-LM1 is a natural human antibody that has shown much promise in […]